Drug Trial Radar · NCT07881224
A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Mar 9, 2027
Study completion Mar 9, 2027
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Oct 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, fixed-sequence, multiple-dose study in approximately 42 healthy adult participants. The study will be conducted in two parts. Part 1 will evaluate the effect of fosmanogepix, through exposure to its active moiety manogepix, on selected CYP enzymes and on the concentration-QT interval corrected for heart rate (QTc). Part 2 will evaluate the effect of manogepix on CYP2C8 and on selected drug transporters. The maximum study duration will be approximately 13.5 weeks for participants in Part 1 and approximately 12 weeks for participants in Part 2.
Conditions
- Healthy Adult Participants
Interventions
FosmanogepixDrug
Fosmanogepix will be administered as an intravenous infusion or as an oral tablet
PlaceboOther
Placebo will be administered as an intravenous infusion or as an oral tablet
The medicine cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan and midazolam)Other
The medicine cocktail will be administered as tablet, capsule, or drink to be swallowed
Probe substrates (repaglinide, rosuvastatin, and digoxin)Other
Probe substrates will be administered as oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Maximum Plasma Concentration (Cmax) of the medicine cocktail when administered alone or in combination with manogepix at steady stateTime frame: At Day 1 and Day 22
- Part 1: Area under the concentration-time curve (AUC) of the medicine cocktail when administered alone or in combination with manogepix at steady stateTime frame: At Day 1 and Day 22
- Part 2: Maximum Plasma Concentration (Cmax) of probe substrate cocktail when administered alone or in combination with manogepix at steady stateTime frame: From Day 1 to Day 20
- Part 2: Area under the concentration-time curve (AUC) of probe substrate cocktail when administered alone or in combination with manogepix at steady stateTime frame: From Day 1 to Day 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Early Clinical & Bioanalytical Solutions
Groningen, Netherlands, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.